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Abstract
Deregulation of a broad range of protein kinases has been linked to the 
 development and growth of cancer cells. Protein kinases are intracellular enzymes 
that regulate cell growth and proliferation as well as the triggering and regulation 
of immune responses. Protein kinases are important therapeutic targets in cancer 
because of their critical role in signalling mechanisms that drive malignant cell 
characteristics. Intensive efforts in drug research have been made in this area over 
the last two decades. The current study delves into the catalytic domain of a protein 
kinase as well as information transfer from the cell’s membrane to internal targets. 
It also discusses the function of protein kinases in signal transduction and their cel-
lular signalling pathways. Furthermore, it specifically outlines a systematic method 
to hybrid therapies to solve the issue of protein kinase resistance. The therapeutic 
use of nitric oxide, as well as other targets such as Phosphoinositide 3-kinases 
(PI3K), Protein Kinase B (Akt), serine/threonine protein kinase (mTOR), p38 
mitogen-activated protein kinases (p38 MAPK), vascular endothelial growth factor 
receptors (VEGFR), epidermal growth factor receptors (EGFR), and anaplastic 
lymphoma (ALK) etc., According to the review article, selective therapy has shown 
high effectiveness in the treatment of advanced cancer, with protein kinase inhibi-
tors being a main focus of the therapy. As a result, the latest review summarized 
that, the current state of science with the aim of identifying a novel protein kinase 
inhibitor that may be utilized in the treatment of advanced cancers.
Keywords: Protein kinases, Signal Transduction, Cellular signalling pathways,  
NO and Anticancer
1. Introduction
The protein kinase enzyme family has been one of the most significant drug 
targets in the 21st century due to the dysregulation of protein kinase function in 
several diseases, including cancer. Protein kinases assume a crucial role in the 
intracellular transduction on account of their capability to phosphorylate plenty 
of proteins. In recent years, various protein kinase inhibitors have been recog-
nized and are being utilized effectively in the clinical sector. In 2020, the FDA 
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approved the following medications for the treatment of the diseases listed: 
gastrointestinal stromal tumors), Capmatinib (non-small cell lung cancer), 
Pemigatinib (cholangiocarcinoma), Pralsetinib and Selpercatinib (non-small cell 
lung cancer, medullary thyroid cancer, and distinguished thyroid cancer), 
Selumetinib (neurofibromatosis type I), and Tucatinib (neurofibromatosis type 
I) (HER2-positive breast cancer). About every part of cellular activity is impli-
cated in protein kinases [1]. It controls the metabolism, cell division and motion, 
movement, as well as immune and nervous system function and programmed cell 
death. The transfer of -phosphate from ATP to its protein substrates is catalyzed 
by protein kinase [2]. Protein kinase is a high-energy phosphate donor enzyme 
that donates a phosphate to other proteins. Phosphorylation is the process of 
converting one substance into another. In the reaction below, the substratum 
receives a group of phosphates and a phosphate group is donated by the high-
energy ATP molecule. Trans-esterification results in a phosphorylated substrate; 
dephosphorylation is generated if the phosphoryphorylated substrate donates a 
phosphate group, and the phosphorylated substrate is grouped with ADP [3]. 
Protein kinases catalyze the following reaction:
 MgATPl Protein OH Protein O:PO32 MgADP H− − − +−+ → + +   
The human genome contains about 500 protein kinase genes, representing 
approximately 2% of all human genes [3]. Tyrosine kinases phosphorylate tyro-
sine hydroxyl groups in their targets, while serine/threonine kinases phosphory-
late serine and threonine hydroxyl groups in their targets [4]. Protein kinases 
can be present in bacteria as well as plants. The majority of cellular pathways, 
especially those involved in signal transduction, are known to be regulated by 
kinases, and their actions can alter up to 30% of all human proteins. Protein 
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kinases are enzymes that phosphorylate serine, threonine, tyrosine, or histidine 
residues in proteins. Phosphorylation can affect the role of a protein in a number 
of ways. It has the ability to alter the function of a protein, stabilise or kill it, 
localise it in a particular cellular compartment, and start or stop its association 
with other proteins. Protein kinases make up the majority of kinases which have 
had a lot of criticism. Phosphatases are involved in the regulation of proteins and 
enzymes, as well as cell signalling. Aside from allosteric regulation, the potential 
to affect protein behaviour is tremendous [3], and there are many methods for 
covalently altering a protein. Allosteric regulation evolved to react to signals 
from inside the cell, while phosphorylation evolved to respond to signals from 
outside the cell, according to Edwin Krebs’ Hopkins Memorial Lecture. The fact 
that eukaryotic cells phosphorylate proteins even more frequently than prokary-
otic cells supports this theory, implying that the more complicated cell form has 
evolved to react to a broader spectrum of signals [5]. The chemical feature of a 
kinase is to covalently attach an ATP phosphate group to one of three amino acids 
with a free hydroxyl group. While most kinases bind to serine and threonine, 
some (dual-specificity kinases) often bind to serine and tyrosine [3]. Protein 
kinases use two types of interactions to identify their physiological substrates 
in cells: (i) the active protein kinase site recognises the consensus phosphoryla-
tion sequence in the protein substratum, and (ii) distal interactions between the 
kinase and the substratum are mediated by binding a docking motif spastically 
isolated from the phosphorylation site in the substratum to a substratum. Protein 
kinases use these interactions to identify their protein substrates with extreme 
precision. The identification of possible protein kinase physiological substrates 
should be aided by understanding the molecular basis for these interactions. 
Since protein phosphorylation is so important, researchers have spent a lot of 
time trying to figure out how protein kinase signal transduction mechanisms 
work. Dysregulation of protein kinases is seen in a wide range of illnesses, 
including cancer and inflammatory conditions.
2. Importance of protein kinase’s
Protein kinases are intracellular enzymes that regulate cell growth and pro-
liferation as well as immune response triggering and control. Protein kinases are 
phosphotransferases that binds phosphate to the side chains of serine, threonine, 
or tyrosine residues in cells to phosphorylate them. Kinases are needed in the first 
phase of intracellular immune cell signalling. Kinases, for instance, bind to the 
intracellular component of receptors on T and B lymphocytes’ cell surfaces, and 
once these receptors are engaged with their extracellular ligands, they trigger intra-
cellular signalling cascades within these cells. Phosphate (P) is transferred from 
ATP to a serine, threonine, or tyrosine residue in protein by protein kinases  
(Figure 1). Phosphorylation acts as a’molecular shift,’ enabling proteins to be 
triggered or deactivated directly. Protein phosphatases, on the other side, catalyze 
the elimination of the -phosphate from the target protein, which inhibits kinase 
function and reverses phosphorylation results [1, 3]. Serine (Ser or S), threonine 
(Thr or T), and tyrosine (Tyr or Y) residues account for more than one third of all 
protein phosphorylation events (O-phosphorylation) [3]. Just 1.8 per cent of tyro-
sine residues are phosphorylated, compared to 86.4 per cent of serine residues, 11.8 
per cent of threonine residues, and 11.8 per cent of tyrosine residues [3, 4]. Tyrosine 
phosphorylation is peculiar among post-transitional modifications (PTM) in the 
EGFR band, including a tyrosine kinase domain. Histidine (His or H) and aspartate 
(Asp or D) metabolites may also be N-phosphorylated, but this process is less robust 
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than other phosphorylation approaches. Since phosphorylation/dephosphoryla-
tion events mediated by different kinases and phosphatases trigger and deactivate 
several enzymes and receptors, protein phosphorylation is a central regulating 
mechanism in several cellular processes, including protein synthesis, cell division, 
signal transduction, cell forming, development, and ageing. In addition, the human 
genome contains 568 protein kinases and 156 protein phosphatases, both of which 
control phosphorylation events and thus play a key role in biological processes such 
as proliferation, differentiation, and apoptosis. Phosphorylation stimulates the p53 
receptor, which stops gene replication, stops the cell cycle, starts DNA repair, and, 
in certain instances, helps the cell die [2]. Chronic inactivation of the p53 protein 
Figure 1. 
Phosphorylation by protein kinase.
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due to excess in the phosphorylation/dephosphorylation pathway will turn a cell 
cancerous. The 568 human protein kinases are classified based on the amino acid 
residues that they phosphorylate. The majority of kinases (serine/threonine kinases, 
or STKs) operate on both serine and threonine, while others (tyrosine kinases, or 
TKs) only work on one of the three amino acids (dual-specificity kinases; DSKs) 
[2]. STKs and TKs can be phosphorylated by the latter [6], with STKs accounting 
for about a quarter of all human protein kinases [2, 7]. STKs phosphorylate serine 
or threonine’s OH group. DNA injury, as well as chemical signals like Ca2+/calmod-
ulin, cyclic adenosine monophosphate/cyclic guanosine monophosphate (cAMP/
cGMP), and diacylglycerol [8–16], trigger them. Protein kinase phosphorylation 
sets off a chain reaction that results in the phosphorylation of various amino acids 
[17]. Kinases may be programmed or deactivated in a variety of ways, including cis- 
or autophosphorylation, binding with activator or inhibitor proteins, or checking 
their localization in the cell with a substrate [3].
3. Catalytic domain of a protein kinase
The catalytic domain of a protein kinase is divided into two parts: N-terminal 
and C-terminal. A peptidic strand connects the two, forming an active site with 
a front pocket (catalytic residues) and a back pocket. A stored lysine residue and 
a residue “gatekeeper” control access to the back pocket. The catalytic domain 
is unavailable while activated since the propellers of the N- and C-terminal sub 
domains move inward. Non-catalytic domains of the kinases allow substrate attach-
ment and signalling protein recruitment [3]. Kinases have gained in popularity in 
recent years, thanks to their functions in signal transduction and amplitude modu-
lation, as well as their importance in signalling [18–20]. Many databases have been 
created to aid in the analysis of phospho-signalling networks [21, 22]. According to 
a review, protein kinases have been linked to over 400 diseases, either directly or 
indirectly. As a consequence, protein kinases are regarded as one of the most signifi-
cant drug targets. Small molecular compounds that inhibit protein phosphorylation 
and thus resist activation can be used to target kinases. These small molecule inhibi-
tors reduce kinase gene expression by disrupting ATP-kinase binding, intervening 
with kinase-protein interactions, and disrupting ATP-kinase binding. Protein 
kinase targets (SYK) include Janus kinase (JAK), mitogen-activated protein kinase 
(MAPK), and spleen tyrosine kinase [1–3].
4. Manifestation of signal transduction
The transmission of information from the cell’s membrane to internal targets 
(within the cell) initiates a chain of molecular events that culminate in a biologi-
cal response to the affector molecule (Figure 2). Advances in biochemical and 
molecular biological techniques have enabled the discovery of essential enzymes 
involved in the transduction phase, as well as the production of several natural 
and synthetic modulators of biological processes, over the last decade [5, 23]. 
Researchers have better understood molecular events in both natural and patholog-
ical settings because of these techniques. As new information regarding molecular 
interactions that regulate cellular responses has become accessible, the potential 
for designing and creating new drugs to cure cancer, central nervous system disor-
ders (Alzheimer’s disease), cardiovascular disorders (hypertension), skin disorders 
(inflammation), diabetes mellitus, and other chronic diseases has grown.
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5. Protein kinase’s role in signal transduction
Second messengers such as cyclic AMP (adenosine monophosphate) and 
calcium are needed for the majority of isozymes to act [24, 25]. Kinases and phos-
phatases are known as “third messengers” because of this. Signal transduction is the 
process by which an extracellular primary signal is converted into an intracellular 
second messenger. In ligand-gated (ion channel) receptors, ion influx serves as 
a second messenger. G-protein-linked receptors can stimulate not only a second, 
but also a third and fourth messenger while they are activated. The ultimate end-
point could be the manipulation of gene transcription to generate messenger RNA 
(mRNA) and then mRNA translation to produce a protein specific to that gene. 
When a receptor attaches to a signalling molecule, it activates a signal transduction 
process. The four forms of messenger systems are as follows:
The first messengers are G-protein-linked messengers, kinases, and phospha-
tases, followed by phospho-calcium/cyclic AMP response element-binding (CREB) 
protein as the fourth messenger.
6. Protein kinase’s role in cellular signalling pathways
Protein kinases play a number of roles in the body [26, 27]. Protein kinases are 
involved in variety of cellular signalling pathways Figure 3 (phosphorylation). 
Protein kinases have different physiological functions in various systems, such as the 
cardiovascular system [27]. Troponin is triggered when PKA is activated, increasing 
the binding of excitation contractions. It also increases the contractility of the heart 
muscle. PKC activation phosphorylates other proteins in smooth muscles, despite 
the fact that cytosolic Ca++ combines with calmodulin (CAM) to activate myosin 
light chain kinase, causing smooth muscle contraction [25, 28]. Protein kinase A 
causes an increase in membrane water permeability by increasing the rate of exocy-
tosis of water-containing vesicles (WCVs) into the apical membrane and decreasing 
the rate of endocytosis of WCVs from the apical membrane in the kidneys. The 
mitogen-activated protein (MAP) kinase pathway is activated by angiotensin I 
receptors (At1) in the kidney, which promotes cell development, especially in vas-
cular and cardiac cells. It raises proton changes, particularly C-fos and C-jun, which 
regulate the transcription of several genes involved in cell growth [23]. At1 activates 
Protein Kinase A, which causes phosphorylation of proteins involved in aldosterone 
synthesis, neurotransmission facilitation, CNS outcomes, and renal impact.
Figure 2. 
The event of signal transduction.
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7. A review of functions of protein kinases
Protein kinases assign a phosphate group from the ATP gamma location to specific 
amino acid residues in proteins and peptides. Protein phosphorylation is implicated 
in a variety of physiological processes, including glucose absorption, signalling, 
epigenetic modifications, and cell cycle progression. Diabetes, cardiovascular disease, 
Alzheimer’s disease, and cancer, to name a few illnesses, have all been linked to phos-
phorylation deficiencies. Monitoring protein kinase activity is crucial for better under-
standing disease molecular mechanisms and determining whether or not a treatment 
is successful. Inhibiting pathological phosphorylation can aid in the treatment of these 
diseases as well [29]. The desire to solve the three-dimensional structures of many 
of these enzymes sparked interest in academia and the pharmaceutical industry due 
to these factors [30]. According to Steinberg SF, cyclin-dependent kinases (CDKs) 
are a form of serine/threonine kinase whose activity is mediated by cyclin, a protein 
regulatory subunit. Eukaryotic cell division and transcription are aided by CDKs. 
PKC is a serine/threonine kinase that regulates a variety of natural cellular responses 
and also plays a role in the pathogenesis of ischemia–reperfusion injury. The Abelson 
murine leukaemia virus (Abl) proto-oncogene is a non-receptor tyrosine kinase that 
is activated by both extrinsic ligands such as growth factor receptors and intrinsic 
Figure 3. 
The protein kinase sequence of signaling process.
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signals such as DNA damage and oxidative stress. c-Abl shuttles between the cytosolic 
and nuclear compartments, phosphorylates a variety of cellular substrates (includ-
ing adaptor proteins, other kinases, cytoskeletal proteins, transcription factors, and 
chromatin modifiers), and controls signalling pathways implicated in actin polym-
erization and cytoskeletal remodelling, cell adhesion and motility, transcriptional 
regulation, and the DNA structure [30]. The mitogen-activated protein kinase 4 
(MKK4) has been discovered to be a central regulator of liver regeneration, according 
to Klövekorn P et al., and could be a valuable drug goal for treating liver diseases by 
restoring the organ’s intrinsic regenerative potential. According to Wüstefeld et al., 
MKK4 is a primary promotor for liver regeneration, with positive results on hepato-
cyte regeneration, robustness, fibrosis, and Fas-mediated apoptosis [31]. The primary 
intracellular energy sensor, according to Jovanovic-Tucovic et al., is AMP-activated 
protein kinase (AMPK), which triggers ATP-generating catabolic pathways while 
inhibiting ATP-requiring processes in response to the increase in the AMP/ATP ratio 
and/or oxidative stress. Depending on the form of stimuli and the intensity/length of 
AMPK activation, this serine/threonine kinase may be neuroprotective or neurotoxic, 
and its dysregulation has been attributed to neurodegenerative disorders including 
Parkinson’s disease. Serine/threonine-protein kinase B/Akt is another crucial protein 
kinase for neuronal cell metabolism and survival. Phosphodiesterase 5A inhibitors, 
such as Sildenafil, have been shown to protect against ischemic injury by decreasing 
cardiac Na+/H+ exchanger (NHE1) activity, which is regulated by protein kinase G, as 
mentioned by Diaz RG et al. [32]. In 1954, Burnett and Kennedy discovered the Casein 
Kinase 2 (CK2) catalyst. It’s a Ser/Thr protein kinase that’s acidophilic and pleiotropic, 
and it’s crucial for cell viability. When coupled with CK1, it acts as a catalyst, phos-
phorylating Casein protein in vitro (but not in vivo) [32]. The use of enacted AMP 
protein kinase as a therapeutic target for ischemia–reperfusion injury was identified 
by Rong Ding et al. [33].
The most popular drug targets include BCR-Abl, B-Raf, vascular endothelial 
growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), 
and ALK. The bulk of small molecule protein kinase antagonists adhere to the 
protein kinase domain and treat cancers such as myelofibrosis, polycythemiavera, 
persistent immune thrombocytopenia, rheumatoid arthritis, idiopathic pulmonary 
fibrosis, and glaucoma [34].
Human eukaryotic protein kinases (ePKs) have been divided into nine classes, 
according to Gaji et al. The following are examples of these: (1) the AGC group, 
which includes PKA, PKB (At1, At2, At3) PKG, and PKC; (2) the Ca2+/calmodulin-
dependent protein kinase (CAMK) group, which includes calcium/calmodulin-
dependent protein kinases (CAMK) and mitogen activated protein kinase activating 
protein kinases (MAPKAPKs); (3) the casein kinase 1 (CK1) group, which has 12 
members; (4) the CMGC group, which has 6161members including cyclin-depen-
dent protein kinases (CDK), mitogen-activated protein kinases (MAPK), glycogen 
synthase kinase (GSK) and cyclin dependent kinase like (CDKL) families; (5) The 
STE group (related to yeast non-mating or sterile genes) has 47 members who are 
MAPK upstream regulators; (6) the tyrosine kinase (TK) group has 90 members, 
including 58 receptor protein kinases (RTKs) and 32 non-receptor tyrosine kinases; 
(7) the tyrosine kinase like (TKL) group has 43 members, and proteins in this 
family; (8) the receptor guanylylcyclase (RGC) group consists of five members; and 
(9) the ‘other’ group has 83 members. In addition, 40 kinases are known as atypical 
kinases, one of which is the mitochondrial pyruvate dehydrogenase kinase [35]. For 
types and classes of protein kinases refer Tables 1 and 2. AMP-activated protein 
kinase (AMPK) senses energy levels and controls metabolic processes to maintain 
homeostasis. The function of AMPK is influenced by the supply of nutrients such as 
carbohydrates, lipids, and amino acids. AMPK function is impaired by overnutrition, 
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inflammation, and hypersecretion of certain anabolic hormones, such as insulin, 
which is exacerbated by food shortages and inhibited by obesity. According to Zhao 
and Saltiel, activating AMPK in the liver inhibits de novo lipogenesis, promot-
ing fatty acid oxidation (β -oxidation). Furthermore, AMPK activation prevents 
hepatic steatosis by inhibiting the production of free fatty acids from adipose tissue 






Acts as a catalyst, allowing intracellular proteins to be catalysed. Glycogen, sugar, and lipid 
metabolism are all regulated by this protein.
Phosphorylate acetyl-CoA carboxylase and pyruvate dehydrogenase in adipocytes, myocytes, 
and hepatocytes, resulting in acetyl-CoA-lipogenesis.





Akt Akt1 Akt2 Akt3
Cell proliferation, apoptosis, 
transcription, and cell 
migration are all involved 
in glucose metabolism. Cell 
survival - both actively and 
indirectly facilitate growth 
factor-mediated cell survival. 
Glycogen synthesis is aided by 
metabolism. Angiogenesis is 
linked to tumour growth and 
angiogenesis.




























The brains of 
mice lacking 






Phosphorylation of intracellular proteins is catalysed by this enzyme, which changes their 
activities. Controls cellular growth and differentiation.
Table 2. 





dependent protein kinase II 
(CaMKII)




Platelet derived growth factor 
(PDGF) receptor
Epidermal growth factor 
(EGF) receptor1
Insulin growth factor (IGF1) 
receptor
Stem cell factor (scf) receptor
Processes alzheimer's amyloid precursor 
protein, epithelial cell migration and 
carcinoma invasion, spermatogonia 




Histidine kinase The histidine kinase family is structurally 
similar to the pyruvate dehydrogenase 
family of kinases in animals.
Mixed kinases Muscle action potential kinase 
(MAPK)
Involved in the cascade of muscle action 
potential kinase
Table 1. 
A summary the types of protein kinases based on amino acid residue.
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AMPK in nutrient absorption by tissues, especially glucose and fatty acid uptake. 
Because of its impact on carbohydrate and lipid metabolism, rising FA oxidation and 
decreasing lipogenesis, AMPK activation has been proposed as a therapeutic goal for 
nutrient overload. In NAFLD/NASH (non-alcoholic fatty liver disease/non-alcoholic 
steatohepatitis), nutrient overload induces hepatic steatosis, which leads to fibrosis 
and liver injury. Hepatic steatosis is the accumulation of ectopic lipids in the liver and 
is closely linked to obesity, insulin resistance and type-2-diabetes.
De novolipogenesis (DNL) from carbohydrates or increased FA absorption 
and triglyceride synthesis cause lipid accumulation in the liver. Increased hepatic 
FA oxidation, on the other hand, reduces steatosis [37]. Li et al. results suggest 
that AMPK may be used as a clinical therapy for the treatment of cholestatic liver 
damage. The ability to evaluate the dose- and time-effects of AMPK activation in 
various models representing various stages of cholestatic liver injury is critical not 
just for determining the efficacy of AMPK as a targeted therapy for treating chole-
static liver injury, but also for providing crucial scientific proof for clinical practice 
and translational studies of existing AMPK inducers [38].
In recent pharmacological study, protein kinases have become one of the most 
widely researched therapeutic targets, especially in cancer and inflammation studies. 
For the treatment of cancer and inflammation, the US Food and Drug Administration 
has licenced 32 small-molecule protein kinase inhibitors. However, no medication suc-
cessfully treats neuroinflammation and/or neurodegenerative conditions due to a lack 
Figure 4. 
Regulation of hepatic steatosis by AMPK.
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of protein kinase drug targets for CNS disorders. According to new findings, some pro-
tein kinases have recently been established as promising drug targets in the treatment 
of neuroinflammation and/or neurodegenerative diseases. Lee and Suk investigated 
a number of protein kinases that are increasingly being seen as potential therapies in 
microglia-mediated neuroinflammation (Figure 5). Because of their critical roles in 
neuronal toxicity, some of these kinases, such as LRRK2, MST1, and tyrosine kinases 
(c-Abl, Src, and Fyn), have been proposed as potential drug targets, while others were 
presented here as novel protein kinase drug candidates because of their critical roles 
in microglial activation [39]. Many neurodegenerative disorders, such as Parkinson’s 
disease (PD), Alzheimer’s disease (AD), and stroke, are due to microglia-mediated 
neuroinflammation. Microglia-mediated neuroinflammation has been compared to 
protein kinases such as leucine-rich repeat kinase 2 (LRRK2) and mammalian Ste20-
like kinase 1 (MST1), Src family protein tyrosine kinases (SFKs), a cellular homolog 
of the Abelson murine leukaemia virus oncogene (c-Abl), and TAM family receptor 
tyros TLRs, TNFR, CD11b, and P2Y12 protein kinases are all known to play a role in 
microglial activation by relaying signals from different exogenous inducers through 
cell surface receptors. Parkinson’s disease and Alzheimer’s disease all have protein 
aggregates as a pathological function (a-synuclein [a-SYN] in PD and Ab peptides in 
AD). These protein aggregates bind to TLR, CD11b, and other microglial receptors, 
triggering a number of intracellular signalling pathways. They are activated as a conse-
quence of neuronal death or other proliferation mechanisms. Bacterial lipopolysaccha-
ride (LPS), adenosine diphosphate (ADP), tumour necrosis factor (TNF), and RNA 
Figure 5. 
Microglia-mediated neuroinflammation.
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virus are among the other triggers that activate microglia through TLRs, P2Y12, and 
TNFR. TAM receptor tyrosine kinases including Axl and Mer are involved in several 
areas of microglia-mediated neuroinflammatory pathology in PD. As a consequence 
of their activation, activated microglia produce a broad variety of proinflammatory 
cytokines, chemokines, and reactive oxygen/nitrogen species (ROS/RNS). In response 
to stimuli and intracellular protein kinases, activated microglia increased migration 
and phagocytic action. Several studies have linked protein kinases to neuronal toxicity 
and microglial activation. In comparison to neurons, only a few protein kinases (PKs) 
have arisen as critical signalling components modulating microglial activation. Some 
kinases, such as Leucine-rich repeat kinase 2 (LRRK2), mammalian Ste20-like kinase 
1 (MST1), tyrosine kinases, and mitogen-activated protein kinases (MAPKs), tend 
to be involved in both neuronal toxicity and microglial activation, while TAM recep-
tor tyrosine kinases (RTKs) like Axl and Mer also recently emerged as new targeted 
therapies for inflammation caused by microglia [39].
According to Simon Diering et al., the modulation of the b1-adrenoreceptor 
(AR) signalling pathway regulates the contraction and relaxation of the heart by 
activating cAMP-dependent protein kinase (PKA) and subsequent cardiac protein 
phosphorylation. The key cardiac protein phosphatases, PP2A and PP1, prevent 
phosphorylation. Intra molecular disulfide formation in the catalytic subunits of 
Figure 6. 
Impact of NO on protein kinases and PKIs activities.
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both kinases and phosphatases inhibits their function [40]. Hashemol hossein 
discovered that CK2 is involved in a number of phases in the biology of striated 
skeletal muscle, including myogenesis and homeostasis in adult muscle, as well 
as neuromuscular junctions, which connect muscle fibres and motor nerves. CK2 
regulates protein import in myotube organelles, as well as the consistency and 
dignity of the postsynaptic machinery in neuromuscular junctions and the muscu-
lar cytoskeleton [40]. It’s also becoming clear that CK2’s function in processes that 
dynamically regulate the phosphoproteome of muscle cells is significant, and that 
it’s likely to play a role in maintaining muscle homeostasis at the molecular level.
A wide range of protein kinase inhibitors (PKIs) have entered various stages of 
clinical development in the last two decades, with various properties and potential 
applications, such as different selectivity and modes of binding to kinases, and 
some have been licenced by the FDA. PKIs have therefore developed themselves 
as a significant class of cancer medicines, and their therapeutic ability continues 
to attract attention. In fact, studying kinase biology in relation to PKI develop-
ment is an essential part of targeted therapies. The resistance of cancer cells to PKI 
therapies necessitates the development of new therapeutic options. As a result, new 
generation PKIs have been built and tested in the hopes of overcoming resistance. 
According to Ghione et al., NO may directly or indirectly regulate protein kinases 
involved in essential cancer signalling pathways, as seen with PKIs. The NO donor 
NTG has been studied in a growing number of clinical trials as an anticancer treat-
ment when combined with radiotherapy or chemotherapy.
NO’s ambivalent impact on PKI (encouraging or inhibiting PKI’s anticancer 
potential) and the action of protein kinases are summarised (regulated at the 
transcriptional or the post-translational level by NO) Figure 6 [41].
8. NO acts as a kinase activator
According to several reports, the intracellular production of NO by NOS is 
needed for the phosphorylation and subsequent activation of EGFR signalling path-
ways. Overexpression of iNOS in a number of tumours, including breast cancer, has 
been related to tumour development and angiogenesis. Indeed, high iNOS expres-
sion has been linked to EGFR phosphorylation, activation, and poor prognosis in 
various breast cancer subtypes.
9. NO acts as a kinase inhibitor
NO has been shown to have a detrimental regulatory impact on protein 
kinases in many experiments, which is compatible with its unclear role in cancer. 
By inhibiting the activity of many protein kinases, NO may inhibit pathways 
implicated in cancer cell proliferation and survival. For some of these protein 
kinases, selective protein kinase inhibitors (PKIs) are currently being  
investigated [41].
Mori et al. investigated whether the biguanide anti-hyperglycemic medication 
metformin dilates retinal blood vessels in rats. In vivo, photographs of the ocular 
fundus were taken with a high-resolution optical fundus camera, and the diameters 
of retinal blood vessels were determined. The pulse rate and systemic blood pres-
sure were also constantly monitored. Metformin (0.01–0.3 mg/kg/min) raised the 
diameters of retinal blood vessels in a dose-dependent way. Metformin’s retinal 
vasodilator effect was blocked by compounds, an AMPK inhibitor, and NG-nitro-L-
arginine methyl ester, a nitric oxide (NO) synthase inhibitor. The AMPK activator 
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5-aminoimidazole-4-carboxamide-1-D-ribonucleoside (AICAR, 0.01–1 mg/kg/
min) generated similar effects. The effects of metformin and AICAR on mean blood 
pressure and heart rate were not important. When NO synthase was inhibited, 
however, a significant presser reaction to AICAR was observed. These findings indi-
cate that metformin activates AMPK, which dilates retinal blood vessels, and that 
NO plays a significant role in the retinal vasodilator reaction after AMPK activation 
(Figure 7). According to this report, the anti-diabetic medication metformin dilates 
retinal blood vessels by activating AMPK, which is the first pharmacological proof 
according to this report. Metformin inhibits inflammatory reactions and angio-
genesis in the retina, in addition to lowering blood glucose levels. Aside from these 
benefits, the retinal vasodilator influence can help prevent or delay the develop-
ment of diabetic retinopathy [42]. KN-93, a calmodulin-dependent protein kinase 
inhibitor, prevents neuronal cell viability in an in vitro Alzheimer’s disease model, 
according to Yilmaz. Alzheimer’s disease is the most prevalent form of dementia 
in people over the age of 65, and it is marked by memory loss that progresses over 
time. The neurofibrillary tangles formed by hyperphosphorylated tau and the 
senile plaques generated by the -amyloid peptide (A 1–4) are the key cardinal 
lesions consistent with Alzheimer’s disease. CaMKII, a central enzyme in memory 
development, incorporates transient knowledge reflecting both past and current 
cellular behaviour into the complex essence of “continuous” calcium signalling. 
Although the alpha and beta isoforms of the CaMKII enzyme have been shown to 
play a role in memory development, the role of the gamma and delta isoforms is yet 
to be determined [43]. Researchers have continued to design and create new Rho 
kinase inhibitors throughout the decade after Fasudil was approved in Japan for the 
Figure 7. 
AMPK activated protein kinase.
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treatment and prevention of cerebral vasospasm and subarachnoid haemorrhage. 
Rho kinase inhibitors have been shown to be useful in the treatment of neurode-
generative conditions, coronary diseases, metabolic syndrome, and glaucoma. Both 
animal and human trials have supported the beneficial effect of Rho kinase inhibi-
tors in the improvement of lung arterial relaxation and remodelling, suggesting 
that they may be useful in the treatment of pulmonary hypertension. According 
to Abedi et al., Rho kinase inhibitors have also been shown to be successful in the 
preventing and treating pulmonary fibrosis, with increasing confirmation that the 
Rho/ROCK signalling system is involved in actinomyosin contraction and actin 
filament assembly. Down regulation of the Rho/ROCK signalling system is aided by 
specific Rho kinase inhibitors. Rho induction has also been linked to other possible 
clinical uses. For example, statins’ action on atherosclerosis has been linked to their 
Rho inhibitory effect, as has simvastatin’s preventive role in chronic pulmonary 
hypertension. Inhibitions of RhoA activity and down regulation of Rho kinase 
activity are thought to be involved in ibuprofen’s beneficial effects in ventilator-
induced lung injury. In humans, the use of a Rho kinase inhibitor has not been 
confirmed to have severe hemodynamic side effects, and it has been shown to have 
excellent tolerability. Based on post-market monitoring, haemorrhage (1.7 percent) 
and hypotension were the most frequent adverse effects recorded for fasudil (0.07 
percent). Rho kinase inhibitors’ protection profile may be their most significant 
benefit in the care of acute lung inflammation acute lung inflammation (ALI). 
However, since these inhibitors are multifunctional, they seem to be more beneficial 
than any other medicinal agents utilised in the care of ALI. Rho kinase inhibitors 
have been shown to improve cell viability in several in vitro trials. In our search 
of the literature, we identified no single report that contrasted the effectiveness 
and/or risks of Rho kinase inhibitors to those of other therapeutic agents. Human 
evidence and clinical trials confirming the beneficial effects of Rho kinase inhibi-
tors in ALI are minimal or non-supportive, despite preclinical studies endorsing the 
beneficial effects of Rho kinase inhibitors in ALI. For example, in the case of sepsis 
and inflammatory diseases, around 150 compounds reached clinical trials based on 
preclinical evidence, none of which were Rho kinase inhibitors, but failed to hit the 
market, indicating the need for improved preclinical efficacy protocols. Finally, it 
appears that up regulation of the RhoA/ROCK signalling pathway is essential in the 
pathogenesis of ALI.
Rho kinase inhibitors have shown in limited preclinical studies to have a high 
potential for preventing the development of ALI. Inflammation, immune cell 
migration, apoptosis, coagulation, contraction, and cell adhesion were all inhibited, 
which had positive effects.
Endothelium barrier impairment and edoema was reduced as a result of 
increased pulmonary endothelial cells. Inhibition of Rho kinase seems to be a 
successful new method for treating ALI [ARDS]. However, more clinical trials are 
needed to back up this hypothesis [44].
p38 MAP kinase inhibitors in signalling pathways as possible neuroprotective 
drugs were studied by Ahmed et al. The discovery of p38 MAP kinase’s connection 
to TNF- and IL-1 synthesis in 1994 established the fact that the net biological effect 
of p38 activation is the downstream development of various inflammatory media-
tors that initiate the activation and recruitment of leukocytes. p38 MAP kinase 
signalling is linked to excitotoxicity (glutamine aggregation in synapses) in astro-
cytes, synaptic plasticity, and tau phosphorylation in neurons, and it leads to 
neuroinflammation. The activity of the p38 MAP kinase may play a role in the 
pathophysiology of a variety of neurodegenerative disorders, including Parkinson’s 
disease (both hereditary and sporadic) and multiple sclerosis. There are four 
different isoforms of the p38 MAP kinase, all of which share roughly 60% 
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homology. The p38a MAP kinase is a major isoform of p38 that is activated under 
inflammatory conditions and is a key player in the synthesis of inflammatory 
mediators. Upstream MAP3Ks normally trigger downstream MAP kinases (MKK3 
and MKK6). MKK3 and MKK6 trigger p38 MAPK through dual phosphorylation on 
Tyr182 and Thr180 once enabled. In neurodegenerative diseases, p38 MAP kinase 
may control hyperphosphorylation of Tau (PHFTau), leading to its dissociation 
from the cytoskeleton and self-aggregation. PHF-Tau is a significant component of 
the neurofibrillary tangles, which are one of the most common aberrant forms seen 
in Alzheimer’s cases. In the astrocytoma cell line U373 MG, p38 MAP kinase medi-
ates substance P (SP)-induced IL-6 expression independently of NF-B activation. 
SP caused p38 MAP kinase phosphorylation, which was independent of p42/44 
MAPK and protein kinase C activation [45]. Gordon et al. found that stimulation of 
protein kinase c delta in response to neurotoxic stressors (a-synuclein, TNF-, LPS) 
plays a crucial role in the induction of dopaminergic neuronal failure. Protein 
kinase c delta deficiency was shown to reduce locomotor deficiencies and decrease 
proinflammatory reaction in the mouse substantianigra in an experimental model 
of Parkinson’s disease. The function of p38 MAP kinase inhibitors in the treatment 
of neurodegenerative disorders has been investigated, with a particular emphasis on 
their regulatory pathways [46]. According to Lund et al., CEP-1347 inhibits cyto-
kine synthesis in human or murine microglia primary cultures as well as monocyte 
or macrophage-derived cell lines stimulated with Ab140 or endotoxins. The MLK 
inhibitor CEP-1347 inhibited the activation of the cJun/JNK signalling pathways in 
stressed neurons.
In PD animal experiments, the inhibitor also reduced neurodegeneration. It is 
important to provide a thorough understanding of the signal transduction mecha-
nisms involved in microglia-mediated inflammation in order to find therapies that 
can be used to cure neurological disorders. The p38 MAP kinase inhibitors and JNK 
signalling pathways specifically allow a better choice to be investigated further 
due to their potential to decrease proinflammatory cytokines production and their 
intracellular signalling pathway [47]. Watts et al., [48] and Wu et al., [49] recently 
published studies that say MAP4K4. According to Wu et al. [49], factors secreted in 
motor neuron cultures trigger MAP4K4.Following MAP4K4 activation, motor neu-
rons die. As a result, MAP4K4 reduction will affect motor neuron viability through 
I attenuation of the c-Jun apoptotic pathway, and (ii) activation of autophagy 
mediated by FoxO1 that reduces protein aggregate accumulation and depicts that 
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the activation of the p38 MAP kinase pathway in various cell types and pathways in 
neurodegenerative diseases.
10. Differential modulation of phosphorylation
In a single cell method, Basken et al. used phosphoproteomics to compare molec-
ular responses to inhibitors that target protein kinases in several tiers of the MAPK 
cascade. They learned a lot regarding oncogenic BRAF signalling in melanoma 
cells, as well as new knowledge about MAPK pathway organisation, phosphoryla-
tion specificity, and off-target responses to therapeutics that are currently in use or 
being developed. The following results may be drawn from the study’s findings:
First, there is a lot of variation between the phosphosites that are substantially 
influenced by MKK1/2 and ERK1/2 inhibitors. There were no answers that were 
specific to MKK1/2 or ERK1/2 inhibitors. This indicates that the signalling system 
is mostly absent of MKK1/2 targets that split upstream of ERK1/2. Comparing the 
BRAF inhibitor vemurafenib to the MKK1/2 inhibitor selumetinib in a previous 
analysis from our lab revealed identical results. The observed results suggest that 
signalling downstream of oncogenic BRAF requires a linear organisation of pro-
tein kinases, from BRAF to MKK1/2, and from MKK1/2 to ERK1/2, rather than a 
bifurcation in the pathway.
Second, the 161 sites controlled by all four MKK1/2 and ERK1/2 inhibitors 
revealed phosphorylation sites most likely to be bona fide targets of the MAPK 
pathway, allowing us to recognise phosphorylation sites most likely to be bona fide 
targets of the MAPK pathway. Moreover, hundreds of phosphosites have been iden-
tified as possible new ERK targets. Just 20% of the 103 phosphosites with Ser/Thr-
Pro sequence specificity for ERK met existing ERK targets, implying 82 additional 
direct phosphorylation targets. A subset of 47 previously unreported phosphosites 
is prioritised as probable ERK1/2 substrates by searching for markers of MAPK sub-
strates, such as proximity to Pro at position P-2 and the inclusion of DEF or DEJL 
docking motifs. The importance of this study is that, considering the fact that more 
than 700 ERK phosphorylation sites have been identified in vitro and/or in vivo, the 
amount of sites yet to be found is uncertain. The use of phosphoproteomics to find 
new substrates is hampered by a lack of understanding of kinase inhibitor specific-
ity, as well as the risk of off-target results. Where a pathway signals linearly, as tends 
to be the case with the enzymes in the MAPK pathway, contrasting the coordinated 
effects of several inhibitors on more than one tier of the kinase cascade, as well as 
sequence determinants of ERK substrates, offers a rigorous filter for specificity. The 
findings indicate that ERK1/2 regulates new types of cellular processes, and they 
add for understanding of the pleiotropy of cellular responses that this important 
signalling kinase may influence.
Third, they discovered that 21 of the phosphosites observed to react to at least 
one of four kinase inhibitors only reacted to one of the four compounds, whilst the 
other three were obviously unresponsive. This serves as a useful filter for detecting 
inhibitor off-target results. Surprisingly, the majority of unambiguous off-target 
phosphosites reacted to the ERK1/2 inhibitor GDC0994, while responses to other 
kinase inhibitors were scarce. This is something to think about if you’re looking 
at ERK1/2 inhibitors as a way to tackle resistance to BRAF and MKK1/2 inhibitor 
combinations. The inhibition of MKK6 by the clinically important MKK1/2 inhibi-
tor trametinib suggests that even a single off-target may be significant. Depending 
on the cell type or stimulus, blocking the p38 MAPK pathway may influence sur-
vival by promoting oncogenic or tumour suppressive results. Despite the fact that 
trametinib’s IC50 for p38 MAPK inhibition was higher than that of MKK1/2-ERK1/2, 
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this concentration range is often used in literature studies. SB203580, a p38 MAPK 
inhibitor, increased the cell inhibitory response to selumetinib, implying that 
inhibiting p38 synergizes with MKK1/2 inhibitors to compromise cell viability in 
melanoma cell lines. CA-MKK6 and p38 MAPK signalling have been shown to shield 
melanoma cells from UV-induced apoptosis, according to previous research. When 
SB203580 was combined with trametinib, the synergistic impact was reduced, 
which we believe is due to trametinib’s off-target influence on MKK6. The findings 
indicate that trametinib’s impact on p38 MAPK may enhance the drug’s effective-
ness in some circumstances.
Finally, they discussed the problem of differential modulation of phosphoryla-
tion targets downstream of BRAF-MKK-ERK signalling. Different proteomics 
studies sometimes see differences in phosphosite responses to the same pathway, 
but cannot differentiate if such results are due to unequal signalling responses or 
experimental heterogeneity. The findings revealed that various cell systems had 
different reactions to the same pathway. However, some of the reported inconsis-
tencies may be explained by methodological differences between laboratories or 
off-target inhibitor results, which the study could not rule out. The authors were 
able to re-address this issue more rigorously after comparing four inhibitors using 
data obtained by one lab in one cell system. Finally, it was discovered that certain, 
but not all, validated ERK1/2 targets are protected from phosphorylation in cell 
system. The significance of this discovery is that nothing is known regarding why 
certain phosphorylation sites that are usually supervised by ERK are bypassed 
under some conditions but are repeatedly attacked under others. Awareness the 
processes that regulate variability in cellular responses may include an understand-
ing of the fundamental mechanisms that contribute to differential regulation 
within the phosphoproteome. The gain of new insight into new targets for control 
by the oncogenic BRAF driver pathway in cancer cells by comparing different 
inhibitors of multiple kinase tiers utilising phosphoproteomics, which is a valuable 
method for assessing the specificity of drugs and drug candidates [50]. The Bender 
and colleagues have shown that significant effect on CK2 and it has a proliferation 
and differentiation of neural stem cells from the sub ventricular region in a sample. 
They reported that proliferative ability is significantly reduced when the enzyme is 
inhibited [51]. CK2 inhibition interrupts the neuronal and glial lineages within a 
three-day time window during differentiation. CK2 kinase function seems to be 
redundant at later levels of differentiation. While it has been established that CK2 
plays a role in nervous system production, knowledge on the role of kinase-depen-
dent pathways in neurogenesis is scarce. This may be attributed to the CK2 or CK2 
knockout mice’s extreme and fatal neurodevelopmental phenotypes. Huillard et al. 
found that disrupting the CK2 subunit induced oligodendrogenesis to be negatively 
regulated. The bHLH transcription factor Olig2, which is one of the main regulators 
of oligodendrocyte growth [52], interacts with CK2. It was also discovered that 
embryonic stem cells lacking tCK2 had a viability deficiency. They also discovered 
that CK2 is needed for neurosphere oligodendroglia differentiation. In the absence 
of CK2, the effect of CK2 is attributed to a defect in the holo enzyme’s CK2 kinase 
activity. Those substrates that are only phosphorylated by the holo enzyme cannot 
be phosphorylated without CK2. It also explains how Drosophila CK2 is involved in 
cell proliferation and survival during brain growth. The nucleolar mushroom body 
miniature (mbm) protein is one of the potential substrates. This protein is thought 
to be involved in nutrient-dependent signalling processes that regulate ribosomal 
expression. The observed findings with inhibitors of CK2 kinase activity clearly 
support the theory that the holo enzyme is the functional type of CK2 involved in 
neurosphere proliferation and differentiation. Furthermore, hereditary disruption 
in embryonic neurogenesis results in decreased neural stem cell proliferation and 
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self-renewal. These results are in line with our findings from postnatal neural stem 
cells originating from the subventricular region that were inhibited. The issue of 
lethality can be solved by using knock-down methods or CK2 inhibitors, which 
allows researchers to explore the postnatal function of CK2 in the nervous system. 
The function of CK2 in the nervous system may be investigated further using these 
methods. As a result, it was discovered that CK2 plays a role in ion channel organ-
isation and synaptic transmission [51]. CX-4945 [Silmitasertib] is a powerful 
inhibitor of CK2’s kinase function that was developed as an anticancer medication. 
CX- 4945 has been shown to have cytotoxic properties in acute lymphoblastic 
leukaemia cells, inhibit pro survival signalling in human breast cancer cells, and 
may be used to treat cancer stem cells in glioblastomas. CX-4945 also appears to 
control osteoblast differentiation in vitro and can function as a splicing regulator. 
CX-4945-treated human mesenchymal stem cells divide into adipocytes in the same 
way as untreated cells do, according to a new report. The inability to prevent 
differentiation was shown to be followed by a lack of CK2 kinase inhibitory activity. 
The function of CK2 in neurogenesis was investigated using CX-4945 in various 
concentrations. The proliferation of neurospheres is inhibited in a dose-dependent 
way, according to this research. Since CK2 can be effectively inhibited, two concen-
trations, 10 and 20 M, were chosen for differentiation experiments. A higher 
concentration of CX 4945 causes apoptosis, which greatly decreases cell numbers 
and attacks stem cells and neuronal precursor cells in particular.
As a result, the effect on neurogenesis at this concentration is due to apoptosis 
rather than a particular inhibition. Despite this, the remaining cells maintain their 
cell cycle distribution. We were able to demonstrate that inhibiting CK2 contributes 
to a significant suppression of neurogenesis as well as a reduction in gliogenesis by 
focusing on the surviving cells during differentiation. We have also seen that the 
effect of CK2 persists for many days during separation and that this effect degrades 
slowly and steadily. The lack of apoptosis was observed when a dosage of 10 M 
CX-4945 was used, indicating that this concentration is non-toxic. In this scenario, 
we found that gliogenesis was inhibited but not neurogenesis, indicating that 
neuronal precursors are more susceptible to apoptosis at higher inhibitor concentra-
tions. Using various concentrations of quinalizarin, they were able to achieve either 
heavy apoptosis or no inhibition of the CK2 kinase activity. The CK2 kinase func-
tion was inhibited by about 40% when 40 M quinalizarin was used. In this event, 
neurogenesis was inhibited but gliogenesis was not. The findings obtained with the 
two inhibitors lead me to believe that neurogenesis inhibition is somehow linked 
to apoptosis activation, whereas gliogenesis inhibition is specifically linked to CK2 
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inhibition. This hypothesis is confirmed by Huillard and Ziercher’s findings, which 
showed that disrupting CK2 subunit expression causes oligo-dendrogenesis to be 
negatively controlled. It appears that the period when CK2 kinase activity is needed 
for differentiation is critical. Although knocking out CK2 in embryonic stem cells 
causes overall developmental failure, lineage finding can benefit from timely 
activation or inhibition of the enzyme within a particular organ system, particularly 
when the enzyme is partially up- or down-regulated. The results indicate that inhib-
iting CK2 for 1–3 days prevents stem cell differentiation. The interdependencies of 
the specific partners, such as neurons and glial cells, are also a significant feature 
of CK2’s function in neurogenesis. Glial cells are well known for producing a wide 
variety of trophic factors and cytokines that can aid in the survival and differentia-
tion of neurons. The current observations in the nervous system are consistent with 
the osteoclast separation results obtained with CX-4945. Furthermore, CX-4945 
was found to suppress RANKL-induced osteoblast differentiation. CX-4945, on the 
other hand, increased BMP2-induced osteoblast differentiation. Another research 
looked at the differentiation of pre-adipocytes into adipocytes and found that the 
activation of the CK2 kinase increased at the start of the differentiation phase and 
decreased as the differentiation progressed. Furthermore, inhibiting CK2 kinase 
activity at the start of differentiation for up to 6 days inhibits differentiation, 
although there was no inhibition of differentiation after day 6. As a consequence, 
these findings are in strong harmony with the neural differentiation evidence 
discussed here. Future experiments with graded up- and down-regulations of CK2 
will reveal whether CK2 is still active in the differentiation fate decision of neurons 
and glial cells [51].
Platelet glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa inhibitors) have a well-
established thrombolytic role in myocardial infarction. Despite this, there is a 
scarcity of information on the mechanism of GP IIb/IIIa inhibitors’cardioprotective 
function in ischemic-reperfusion injury (IR). 120 minutes of coronary ischemia 
and 180 minutes of reperfusion were provided to Sprague–Dawley rats. PKC 
(chelerythrine), PI3 kinase and Akt (wortmannin), p38 MAPK (SB203582), p42/44 
MAPK (PD98059), and ERK1/2 (u0126) inhibitors were provided by continuous 
intravenous infusion at a rate of 2 ug/kg/min 30 minutes prior to reperfusion with/
without inhibitors of PKC (chelerythrine), PI3 kinase and Western blot analysis was 
used to isolate and analyse proteins. The apoptotic index (AI) was determined as the 
percentage of myocytes positive for terminal deoxynucleotidyltransferase-mediated 
dUTP-biotin nick-end labelling of all myocytes stained with 4′, 6-diamidino-
2-phenylindole and the ratio of myocardial necrotic region to the area at risk 
(AAR). The GP IIb/IIIa inhibitor decreased the ratio of myocardial necrotic region 
to AAR and AI, as well as exerting an immediate cardioprotective impact by phos-
phorylating and triggering multiple signalling pathways such as PKC, PI3 kinase, 
Akt, p38 MAPK, p42/44 MAPK, and ERK1/2. Raf and MEK1/2 phosphorylation, 
on the other hand, did not show any major rises. Chang et al., found that inhibiting 
GP IIb/IIIa decreased the level of cardiac IR and greatly reduced myocyte apoptosis 
in rats. Furthermore, the cardioprotective influence was induced by several signal 
transduction pathways activation [53].
Linagliptin-induced vasodilation was studied by Seo et al., in a concentration-
dependent manner. The absence of endothelium, as well as pre-treatment with a 
nitric oxide synthase inhibitor (L-NAME) or a small-conductance Ca2+-activated 
K+ channel inhibitor, had little impact on the vasodilatory effect of linagliptin 
(apamin). Furthermore, the adenylyl cyclase inhibitor SQ22536, the protein kinase 
A (PKA) inhibitor KT5720, the guanylylcyclase inhibitor ODQ, and the protein 
kinase G (PKG) inhibitor KT5823 had no impact on linagliptin’s vasodilatory effect. 
Y-27632, on the other hand, greatly reduced linagliptin-induced vasodilation by 
21
Importance of Protein Kinase and Its Inhibitor: A Review
DOI: http://dx.doi.org/10.5772/intechopen.98552
inhibiting Rho-associated protein kinase. The function of ion channels in lina-
gliptin’s vasodilatory effect was also examined. Glibenclamide (ATP-sensitive K+ 
channels), Ba2+ (inwardly rectifying K+ channels), 4-AP (voltage-dependent K+ 
channels), and paxilline (large conductance Ca2+-activated K+ channels) were not 
found to influence linagliptin-induced vasodilation. Furthermore, nifedipine, 
an inhibitor of L-type Ca2+ channels, and thapsigargin, an inhibitor of the sarco-
plasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, had no impact on 
linagliptin’s vasodilatory effect. The inhibition of Rho-associated kinase, but not the 
endothelium, cAMP-PKA or cGMP-PKG-dependent signalling pathways, K+ chan-
nels, Ca2+ influx, or the SERCA pump, could be responsible for linagliptin-induced 
vasodilation [54].
PKCs are thought to control certain pancreatic functions in natural acinar cells, 
ductal cells, and islets, as well as in disease states such as insulin tolerance, diabetes 
mellitus, pancreatitis, and pancreatic ductal adenocarcinoma, according to Fleming 
and Storz (PDA). PKCs control secretory processes in the regular pancreas, as 
shown by amylase secretion in acinar cells, bicarbonate secretion in ductal cells, and 
glucagon and insulin secretion in islets. PKCs play a role in the production of insulin 
tolerance and diabetes mellitus by regulating -cell proliferation and activity, as well 
as insulin secretion and cell death. PKCs play a crucial role in pancreatic injury and 
inflammation, as well as trypsinogen activation and basolateral exocytosis, dur-
ing pancreatitis. PKCs eventually play a role in the growth of PDA by promoting 
acinar cell dedifferentiation (PKC) and acinar-to-ductal metaplasia (PKC). PKC 
control proliferation and promote anchorage-independent development throughout 
the progression of PDA. Atypical PKCs have also been linked to the regulation of 
metastasis. In conclusion, PKC isoforms play a variety of roles in normal pancreatic 
regulation, but they may also play a role in the onset and development of pancreatic 
disease [55].
Mitochondrial ATP synthase, a significant ATP supply in respiring cells, 
should be regulated in both quantity and action to react to differing ATP demands. 
Sugawara et al., screened 80 protein kinase inhibitors and discovered that four of 
them decreased mitochondrial ATP synthesis function in HeLa cells. Knocking 
down their target kinases (PKA, PKCd, CaMKII, and smMLCK) consistently 
resulted in lower mitochondrial ATP synthesis output. The mitochondria of 
smMLCK-knockdown cells only possessed a limited amount of ATP synthase, 
whereas the a- and b-subunits of ATP synthase were formed normally, implying 
that smMLCK affects ATP synthase assembly (or decay) [56].
PIM (proviral insertion in murine) Kinases are a kind of proto-oncogene that 
phosphorylates the target proteins’ serine/threonine residues. PIM-1, PIM-2, and 
PIM-3 are the three groups that play an important regulatory function in signal 
transduction cascades by facilitating cell survival, proliferation, and drug tolerance. 
These kinases are overexpressed in a variety of solid and hematopoietic tumours, 
supporting malignant cell growth and survival in vitro and in vivo by controlling 
cell cycle and inhibiting apoptosis. They are constitutively active until transcribed 
and they lack a regulatory domain. PIM kinases are thought to be essential down-
stream effectors of oncoproteins that overexpress and aid in the mediation of drug 
resistance to available agents like rapamycin. According to Panchal and Sabina, PIM 
kinases have special hinge regions where two Prolines exist, which makes ATP bind-
ing unique while also providing a focus for a growing array of potent PIM kinase 
inhibitors. Preclinical trials of such inhibitory compounds in different cancers sug-
gest that they have positive efficacy, and some of them are currently being studied. 
In their study, they described the molecular mechanism and signalling mechanisms 
of PIM kinases, as well as matriculation in multiple cancers and a list of commonly 
used inhibitors [57]. Dengue virus (DENV) infection is a disease that is common to 
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many areas of the world, and its rising incidence places it among the diseases that 
pose a serious public health danger. Dengue fever (DF), dengue hemorrhagic fever 
(DHF), and dengue shock syndrome are among the clinical symptoms of DENV 
infection (DSS). Extreme dengue fever is characterised by increased proinflam-
matory cytokines and vascular permeability, all of which trigger organ damage. 
Sreekanth et al. used hepatic cell lines, mouse models, and autopsy specimens from 
DENV-infected patients to observe symptoms of liver damage, and these signs 
substantiated the results of inflammatory responses and hepatic cell apoptosis. 
During viral infections, MAPK are implicated in inflammatory responses and 
cellular tension. MAPK signalling has been implicated in inflammatory responses 
and hepatic cell apoptosis in both in vitro and in vivo models, according to published 
evidence. In DENV infection, modifying MAPK signalling reduces inflammatory 
responses and hepatic cell apoptosis. This body of knowledge about the function of 
MAPK signalling in inflammatory responses and cell apoptosis in DENV infection 
is illuminating, and it could speed up the creation of new or repositioned therapies 
to treat this unpredictably disabling disorder [58].
11. Conclusion
In this study, we have addressed the role of protein kinase in human cells and the 
effects of protein kinase inhibitors in the treatment of various diseases and disor-
ders. Protein kinase is a type of kinase enzyme that adds phosphate groups to other 
proteins chemically (i.e. phosphorylation). Many biochemical signalling pathways 
within cells (i.e. signal transduction) and effectors in cellular functions, such as 
cell proliferation and necrosis, are influenced by this enzyme. Protein kinases are 
the third messenger mechanism, and most of their isoforms depend on second 
messengers like cAMP and calcium to function. Overexpression of protein kinase, 
on the other hand, causes life-threatening diseases such as cancer, cardiovascular 
disease (hypertension), central nervous system disease, skin disease (inflamma-
tion), diabetes mellitus, and so on. Moreover, the findings of various researchers 
has also added to the fact. There are currently a range of protein kinase inhibitors in 
the market that inhibit protein kinase activity. They can be used to regulate the cel-
lular responses that protein kinase activity causes. As a result, there is scope for the 
design and production of new medicines that inhibit protein kinase overexpression 
for the prevention and treatment of associated disorders. The functions of protein 
kinases in signal transduction, the effects of overexpression, and the therapeutic 
roles of various protein kinase inhibitors are all discussed here. As a result, further 
research into the protein kinase is needed in order to develop more potent and effec-
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